Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer's Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD

• Published in: Journal of clinical medicine 2019-03, Vol.8 (3), p.341
• Main Authors: Hwang, Jihye, Jeong, Jee Hyang, Yoon, Soo Jin, Park, Kyung Won, Kim, Eun-Joo, Yoon, Bora, Jang, Jae-Won, Kim, Hee Jin, Hong, Jin Yong, Lee, Jong-Min, Park, Hyuntae, Kang, Ju-Hee, Choi, Yong-Ho, Park, Gilsoon, Hong, Jinwoo, Byun, Min Soo, Yi, Dahyun, Kim, Yu Kyeong, Lee, Dong Young, Choi, Seong Hye
• Format: Article
• Language: English
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm8030341

We aimed to present the study design of an independent validation cohort from the Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's disease (AD) (KBASE-V) and to investigate the baseline characteristics of the participants according to the AD clinical spectrum. We recruited 71 cognitively normal (CN) participants, 96 with subjective cognitive decline (SCD), 72 with mild cognitive impairment (MCI), and 56 with AD dementia (ADD). The participants are followed for three years. The Consortium to Establish a Registry for AD scores was significantly different between all of the groups. The logical memory delayed recall scores were significantly different between all groups, except between the MCI and ADD groups. The Mini-Mental State Examination score, hippocampal volume, and cerebrospinal fluid (CSF) amyloid-β42 level were significant difference among the SCD, MCI, and ADD groups. The frequencies of participants with amyloid pathology according to PET or CSF studies were 8.9%, 25.6%, 48.3%, and 90.0% in the CN, SCD, MCI, and ADD groups, respectively. According to ATN classification, A+/T+/N+ or A+/T+/N- was observed in 0%, 15.5%, 31.0%, and 78.3% in the CN, SCD, MCI, and ADD groups, respectively. The KBASE-V showed a clear difference according to the AD clinical spectrum in neuropsychological tests and AD biomarkers.